BioSpace News Archive

Active construction site with cranes, workers, builders and skyscrapers under development. Process of building. Vector illustration. Line art style. Isometric view of a monolithic frame building.

Manufacturing

Niowave, fresh from Novartis deal, starts building $75M radioisotope plant

Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.

May 26, 2026

·

2 min read

·

Nick Paul Taylor

Business

Lilly is pharma’s top dog, placing first in innovation and invention: IDEA

Eli Lilly is the first pharma company to take first place in both categories in the eight years that intelligence firm IDEA Pharma has put out its analysis. Skyrocketing sales and multiple FDA approvals helped the company shoot to the top.

May 26, 2026

·

2 min read

·

Tristan Manalac

Business team running towards goal step by step, Timeline, Short-term, medium-term and long-term business goals concept, Corporate success target creation, Flat vector design illustration.

Duchenne muscular dystrophy

REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies

Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.

May 26, 2026

·

9 min read

·

Heather McKenzie

Vector illustration of a businessman in silhouette being powerfully punched by a giant boxing glove. Symbolizes aggressive competition, business failure, or zero-sum game.

Drug Development

4 troubled targets that have thwarted biopharma

The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.

May 26, 2026

·

9 min read

·

Tristan Manalac

Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins

Gene editing

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. The pharma acquired the asset last year in the $1.3 billion Verve Therapeutics buy.

May 26, 2026

·

2 min read

·

Tristan Manalac

Covid-19 vaccine race concept. Syringes flying like a missile, rocket, or jet plane. Blue background

Mergers & Acquisitions

Lilly lands vaccine trifecta with 3 new biotech buys valued at up to $3.8B

Eli Lilly, with a busier-than-ever business development team, has made a major vaccine play‚ months after hiring veteran vaccine regulator Peter Marks following his FDA departure.

May 26, 2026

·

5 min read

·

Annalee Armstrong

Chicago Cityscape at Sunset with Lakefront View. Aerial view of Chicago skyline at sunset, showing Lake Michigan shoreline, tree-lined parks, and a busy roadway along the waterfront

Cancer

All eyes on Revolution, bispecific antibodies and more at ASCO26

Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.

May 26, 2026

·

6 min read

·

Brianna Abbott

Press Releases

Allergan Aesthetics launches HArmonyCa® with Lidocaine, Canada’s first dual-action, next generation collagen-stimulating injectable

May 26, 2026

·

6 min read

Press Releases

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis